Brad Jacobs to step down from XPO and GXO chairman roles, focus on QXO

Investing.com -- Adaptive Biotechnologies Corp (NASDAQ:ADPT) stock rose 4.3% in Monday premarket trading following the announcement of two non-exclusive agreements with Pfizer Inc (NYSE:PFE) that could be worth up to $890 million.

The commercial stage biotechnology company revealed a target discovery agreement to identify disease-specific T-cell receptors (TCRs) in rheumatoid arthritis and a data licensing agreement for Pfizer to access Adaptive’s proprietary TCR-antigen datasets for research and development in multiple immunology applications.

Under the rheumatoid arthritis agreement, Adaptive will lead target discovery activities to identify disease-specific RA TCRs, while Pfizer will handle all development and commercialization of therapies identified through this work. Adaptive will receive an upfront payment and may be eligible for additional payments in data delivery, development, commercial, and sales milestones potentially totaling up to $890 million.

The second agreement involves Pfizer licensing certain Adaptive TCR-antigen data to develop and train AI and machine learning models for accelerating research and drug discovery across multiple disease areas. For this non-exclusive, multi-year data access agreement, Adaptive will receive an upfront payment and potential future annual licensing fees, though specific financial terms were not disclosed.

Adaptive has generated what it describes as the largest and highest quality TCR-antigen binding dataset compared to what is publicly available, which can potentially inform discoveries across immunology programs.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Investing.com -- ZIM Integrated Shipping Services Ltd (NYSE:ZIM) stock rose 4% following a report that Mediterranean Shipping Company (MSC) has submitted a bid to acquire the Israeli shipping firm.

According to Israeli news website Calcalist, MSC has emerged as a key competitor to Hapag-Lloyd, which had previously expressed interest in acquiring ZIM. The report did not disclose the source of this information.

The potential acquisition has raised concerns domestically. ZIM’s union reportedly met with Transportation Minister Miri Regev on Thursday, requesting that the government use its "golden share" in the company to block any sale to a foreign entity. Regev indicated she would bring the matter before Israel’s security cabinet.

ZIM shares were trading up 6% in premarket trading when the news first broke. The company, which operates in the global container shipping sector, has become an acquisition target amid ongoing consolidation in the shipping industry.

Neither ZIM nor MSC has officially confirmed the bid or commented on the report. If confirmed, this would represent a significant development in the maritime shipping sector, potentially creating a new competitive landscape among global shipping giants.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Investing.com -- HCA Healthcare’s long run of outperformance is leaving little room for error, Morgan Stanley said as it downgraded the largest U.S. hospital operator to Underweight, arguing that key tailwinds are likely to fade just as the stock trades at a peak valuation.

The bank kept its price target unchanged at $425, but said HCA’s strong execution over the past five years has already been fully reflected in the share price.

HCA has outperformed the Nasdaq and the broader healthcare sector by 120% and 175%, respectively, over that period, helped by a post-Covid rebound in patient volumes, expanding scale in fast-growing states such as Texas and Florida, and a sharp rise in Affordable Care Act enrollment.

Morgan Stanley said those drivers are now moderating. The stock is trading at a new peak multiple, while several policy-related supports that have boosted earnings are expected to ease.

Analysts noted that HCA has experienced drawdowns of roughly 15% to 40% in each of the past five years, more than double typical market corrections, underscoring limited tolerance for any disappointment.

ACA subsidies and Medicaid supplemental payments have been a major contributor to growth. Exchange enrollment doubled between 2021 and 2025, lifting admissions and improving payer mix, with ACA-related revenue now accounting for about 10% of total revenue. Supplemental payments generated about $4.9bn of revenue in 2024, roughly 7% of total revenue, with high margins contributing meaningfully to EBITDA.

Morgan Stanley said both supports are likely to become less powerful over time. Its base case sees equivalent admissions growth slowing to about 2.4% in 2026, with a wider range depending on policy outcomes.


While HCA’s resiliency program could help cushion margins, the bank said the current valuation implies a need for further upside, not just stability.

Within the hospital sector, Morgan Stanley said it prefers peers with more attractive valuations and clearer catalysts, pointing to Tenet Healthcare as offering better risk-reward given its discount to HCA and a more aggressive capital return profile.

The bank flagged potential risks to its Underweight view, including stronger-than-expected benefits from AI adoption, continued heavy share buybacks, or higher utilization and patient acuity.

Even so, it said HCA’s combination of slowing growth and peak valuation makes the stock less compelling after years of strong gains.

Investing.com -- STMicroelectronics NV ADR (NYSE:STM) stock rose 2.3% in premarket trading Monday after the semiconductor company highlighted its decade-long partnership with SpaceX that has been crucial for the Starlink satellite internet service.

The collaboration has produced billions of co-designed products used in millions of Starlink user terminals and over 10,000 satellites. STMicroelectronics provides custom-made chips that enable Starlink’s phased-array antennas to deliver high-speed internet to more than 8 million customers across 150+ countries.

According to the announcement, Starlink products are co-designed with ST engineers in France and Italy, with manufacturing taking place in facilities across France, Malta, and Malaysia. The partnership leverages ST’s BiCMOS chip technology for the high-performing phased-array antennas in Starlink terminals.

"We are proud to celebrate a decade of collaboration with SpaceX," said Remi El-Ouazzane, President of Microcontrollers, Digital ICs, and RF Products Group at STMicroelectronics. "Through co-designing key chips, providing engineering services and delivering high-volume manufacturing, we demonstrate the exceptional value of ST’s innovation and manufacturing capabilities."

The semiconductor company has scaled its panel level packaging operations to deliver over 5 million chips daily to support Starlink’s rapid expansion. Beyond the antenna technology, Starlink also uses multiple ST products including STM32 microcontrollers, secure elements, and GNSS across its satellite constellation and infrastructure.

The companies plan to continue their collaboration, focusing on next-generation satellites and user terminals while advancing key enabling technologies for phased-array antennas powered by ST’s BiCMOS-based solutions.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Investing.com -- Amphastar Pharmaceuticals (NASDAQ:AMPH) stock gained 2.3% in Monday’s premarket trading after the company announced FDA approval of its teriparatide injection, a generic equivalent to Eli Lilly’s (NYSE:LLY) FORTEO.

The approval marks Amphastar’s first pen device combination product, which is indicated for treating osteoporosis in various patient populations. According to IQVIA data, the overall U.S. market for teriparatide injection reached approximately $585 million for the 12 months ended September 30, 2025.

Amphastar plans to launch the product by the end of the year, with the drug manufactured at its U.S. facility. This domestic production capability provides a potential advantage in the market where many competitors rely on overseas manufacturing.

"We are proud to announce FDA approval of Amphastar’s first-ever pen device combination product, demonstrating our continued commitment to advancing innovative approaches for complex drug delivery mechanisms," said Dr. Jack Zhang, Amphastar’s President and CEO.

The company’s pipeline includes two ANDAs and one biosimilar insulin filed with the FDA targeting products with a combined market size exceeding $1.8 billion. Additionally, Amphastar is developing three biosimilar products targeting a market exceeding $6 billion and two generic products targeting a market of over $1 billion.

Amphastar has also entered into an exclusive license agreement with Anji for the development of three proprietary peptides targeting cancer treatment and wet age-related macular degeneration.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Investing.com -- Jefferies upgraded Viking Holdings to Buy while downgrading Norwegian Cruise Line Holdings to Hold in a note on Monday, citing diverging growth visibility and balance sheet trajectories heading into 2026.

In a sector-wide outlook, Jefferies analyst David Katz told investors that it is “bullish group-wide” for 2026, applying criteria focused on “business and management quality, visible growth, and reasonable valuation.”

Within that framework, the firm said it is “upgrading VIK to Buy on sustained growth in capacity and pricing,” while “downgrading NCLH to Hold on strategic shifts and sustained leverage.”

Katz argued that European exposure should be a key differentiator for cruise operators. 

Addressing concerns over Norwegian’s recent redeployment of capacity, the analyst stated: “Don’t sweat the Caribbean, look to Europe,” adding that operators with greater European exposure “should benefit vs. Caribbean-focused operators.” 

Jefferies noted that Viking, with 61% exposure to Europe, stands to gain from reduced competition, particularly if geopolitical conditions improve and fuel prices ease.

The Viking upgrade reflects what Jefferies described as “continued strong growth and business model quality, and beneficial positioning in luxury.” 

The firm expects “industry-leading net yield growth of 5% and 4% in FY26-FY27,” alongside high-teens EBITDA growth and “a FCF conversion rate of ~100%,” supporting sub-1.0x leverage and capital returns.

By contrast, Jefferies believes Norwegian faces mounting challenges. 

“Continued slippage on expectations for deleveraging, paired with a rushed capacity and strategy shift,” have tempered its view.

The firm warned that moving “10% of FY26 capacity from Europe to the Caribbean on short notice is likely to interrupt normal bookings and result in yield headwinds,” while leverage expectations have worsened materially.